Skip to main content

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer

By: PR Leap
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
(PRLeap.com) Aachen, Germany, 30 September 2024 - Grünenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and member of the Corporate Executive Board, will assume the role of Chief Commercial Officer (CCO) effective 1 October 2024. Prior to his role as CSO, he was Head of Strategy and Portfolio at Grünenthal.

Jan Adams has over two decades of experience in the pharmaceutical and healthcare industry. Since joining Grünenthal in 2017, he has been key in driving the company's transformational journey. Under his leadership, Grünenthal successfully built a state-of-the-art R&D organisation, redefined its R&D strategy, and built an industry-leading pipeline focused on delivering innovative treatments for acute and chronic pain. Before assuming the role of CSO, he served as Head of Strategy and Portfolio, working at the interface between Strategy, R&D, and Commercial. His role was instrumental in several successful M&A projects and Grünenthal's entry into the U.S. market. Before joining Grünenthal, he held positions with increasing responsibilities at Takeda, McKinsey & Company, and Novartis. Jan Adams started his career as a resident in cardiology. He is a Medical Doctor by training, married, and has two children.

Jan Adams succeeds Janneke van der Kamp, who will leave Grünenthal to pursue an opportunity outside the company.

About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better - and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of �1.8 billion.

More information: https://www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Instagram: grunenthal

GET IN TOUCH
Florian Dieckmann
Grünenthal Gruppe
+49 241 569-2555
https://www.grunenthal.com/

You can see the original version and more on PRLeap here: http://www.prleap.com/pr/299736/grunenthal-appoints-dr-jan-adams-as-chief-commercial-officer

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  258.45
+4.74 (1.87%)
AAPL  338.98
+2.85 (0.85%)
AMD  615.52
+55.70 (9.95%)
BAC  57.96
+0.23 (0.40%)
GOOG  350.87
+6.46 (1.88%)
META  741.25
+75.50 (11.34%)
MSFT  501.61
+7.83 (1.59%)
NVDA  227.38
+5.11 (2.30%)
ORCL  148.56
+0.95 (0.64%)
TSLA  375.30
+11.03 (3.03%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.